Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung
Lung Cancer

Interventions: Drug: Nexavar (Sorafenib, BAY43-9006)
Drug: Bevacizumab
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2010-02-17

Last Posted Date: 2013-11-13

Lead Sponsor: Bayer

Target Recruit Count: 33

Registration Number: NCT01069328

Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Triple Negative Metastatic Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Bevacizumab
Drug: Capecitabine

First Posted Date: 2010-02-17

Last Posted Date: 2016-03-17

Lead Sponsor: ARCAGY/ GINECO GROUP

Target Recruit Count: 64

Registration Number: NCT01069796

Locations: 🇫🇷
Centre Paul Papin, Angers, France
🇫🇷
Hôpital Privé Clairval, Marseille, France
🇫🇷
Centre Hospitalier Bretagne Atlantique, Vannes, France

and more 14 locations

The Valentines Trial

Phase 4

Completed

Conditions: Instent Restenosis

First Posted Date: 2010-02-10

Last Posted Date: 2011-06-17

Lead Sponsor: Eurocor GmbH

Target Recruit Count: 276

Registration Number: NCT01066832

Locations: 🇳🇱
UMC Utrecht, Utrecht, Netherlands
🇮🇹
Policlinico, Modena, Italy
🇩🇪
Heart Center Munich at the Isar, Munich, Germany

Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients

Phase 2

Completed

Conditions: Gastric Cancer

Interventions: Drug: olaparib
Drug: Placebo
Drug: paclitaxel

First Posted Date: 2010-02-05

Last Posted Date: 2023-07-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 124

Registration Number: NCT01063517

Locations: 🇰🇷
Research Site, Taegu, Korea, Republic of

Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel
Drug: vadimezan

First Posted Date: 2010-01-27

Last Posted Date: 2013-04-10

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 17

Registration Number: NCT01057342

Locations: 🇨🇭
Inselspital Bern, Bern, Switzerland
🇨🇭
Spitalzentrum Biel, Biel, Switzerland
🇨🇭
Saint Claraspital AG, Basel, Switzerland

and more 9 locations

Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma

Phase 2

Terminated

Conditions: Angiosarcomas
Soft Tissue Sarcoma

Interventions: Drug: Bevacizumab
Drug: Paclitaxel

First Posted Date: 2010-01-25

Last Posted Date: 2018-03-26

Lead Sponsor: Stanford University

Target Recruit Count: 18

Registration Number: NCT01055028

Locations: 🇺🇸
Santa Monica Sarcoma Center, Santa Monica, California, United States
🇺🇸
MD Anderson Sarcoma Center, Houston, Texas, United States
🇺🇸
Stanford University Medical Center, Stanford, California, United States

A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer
Adenocarcinoma

First Posted Date: 2010-01-20

Last Posted Date: 2017-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 2

Registration Number: NCT01051934

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen

Phase 1

Completed

Conditions: Breast Neoplasms
Breast Cancer

Interventions: Drug: XL147 (SAR245408)
Biological: trastuzumab
Drug: paclitaxel

First Posted Date: 2010-01-06

Last Posted Date: 2016-06-03

Lead Sponsor: Sanofi

Target Recruit Count: 42

Registration Number: NCT01042925

Locations: 🇪🇸
Investigational Site Number 3413, Madrid, Spain
🇺🇸
Investigational Site Number 1150, New York, New York, United States
🇺🇸
Investigational Site Number 1238, Fort Meyers, Florida, United States

and more 6 locations

Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors

Phase 2

Conditions: Ovarian Gynandroblastoma
Ovarian Sertoli-Leydig Cell Tumor
Ovarian Sex Cord Tumor With Annular Tubules
Ovarian Sex Cord-Stromal Tumor
Ovarian Sex Cord-Stromal Tumor, Not Otherwise Specified
Ovarian Steroid Cell Tumor
Ovarian Granulosa Cell Tumor

Interventions: Biological: Bleomycin Sulfate
Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Drug: Cisplatin
Drug: Etoposide Phosphate
Drug: Paclitaxel

First Posted Date: 2010-01-05

Last Posted Date: 2022-01-25

Lead Sponsor: GOG Foundation

Target Recruit Count: 63

Registration Number: NCT01042522

Locations: 🇺🇸
MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore, Maryland, United States
🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

and more 216 locations

Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer

Phase 2

Terminated

Conditions: Endometrial Adenocarcinoma
Stage II Uterine Corpus Cancer
Stage IVA Uterine Corpus Cancer
Stage IB Uterine Corpus Cancer
Stage IIIA Uterine Corpus Cancer
Stage IIIC Uterine Corpus Cancer
Stage IVB Uterine Corpus Cancer
Stage IA Uterine Corpus Cancer
Stage IIIB Uterine Corpus Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Radiation: Internal Radiation Therapy
Radiation: External Beam Radiation Therapy
Other: Laboratory Biomarker Analysis

First Posted Date: 2009-12-30

Last Posted Date: 2023-10-26

Lead Sponsor: Albert Einstein College of Medicine

Target Recruit Count: 31

Registration Number: NCT01041027

Locations: 🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy